Xlife Sciences AG: Transaction with Baliopharm AG
Xlife Sciences AG / Key word(s): Contract Xlife Sciences AG: Transaction with Baliopharm AG License Deal of 300 million euros successfully completed On the 18th of December, Baliopharm AG received the approval to start Phase I of medical drug Atrosimab for the treatment of Non-Alcoholic SteatoHepatitis (NASH) by the Australian Healthcare Administration. NASH is the most frequent chronic liver disease. The Global Liver Institute estimates that there are more than 115 million people affected globally by NASH. According to the Institute, this number could double by 2030. In Germany, 1.5 to 2 million patients have at least a mild form of NASH. Under more severe circumstances, the disease can lead to irreversible liver damage (liver cirrhosis) and cannot be treated therapeutically. In this way, Baliopharm AG views this as a huge market.
08-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Xlife Sciences AG |
Klausstrasse 19 | |
8008 Zürich | |
Switzerland | |
Phone: | 0041 44 385 84 60 |
E-mail: | info@xlifesciences.ch |
Internet: | www.xlifesciences.ch |
ISIN: | CH0461929603 |
WKN: | A2PK6Z |
Listed: | Regulated Unofficial Market in Frankfurt, Munich |
EQS News ID: | 1159182 |
End of Announcement | DGAP News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: